International Journal of Research & Review (www.ijrrjournal.com) 378 Vol.6; Issue: 10; October 2019 International Journal of Research and Review www.ijrrjournal.com E-ISSN: 2349-9788; P-ISSN: 2454-2237 Original Research Article Monitoring Hypertension with Azilsartan Treatment With/Without Added Drug in PatientsWith/Without Comorbidity: An Observational Study Preeti Gupta 1 , Sandeep Bansal 2 , Anunay Gupta 1 1 Assistant Professor, 2 Professor and Head, Department of Cardiology, Vardhman Mahavir Medical College (VMMC) and Safdarjung Hospital, Ministry of Health and Family Welfare, Government of India, New Delhi- 110029, India. Corresponding Author: Preeti Gupta ABSTRACT Aims and Objectives of Study: Hypertension statistics had reported that approximately 9 million lives/per annum are at risk due to increased blood pressure. Azilsartan Medoxomil is an angiotensin inhibitor, widely used as a single treatment regime or in combination with other drugs is an FDA approved therapeutic that has a significant impact in hypertension patients. The present study is a prospective observational study with (a) Primary objective: to evaluate efficiency of Azilsartan (40mg / 80mg) as single treatment regime or with added drug, (b) Secondary objective: to assess the control statistics of hypertension in patients with/ without comorbidity. Methodology: A total of 120 patients were screened and 100 subjects fulfilled the inclusion criteria with a hypertensive cut off value of 130/80 mmHg. Patients were subjected to Azilsartan monotherapy dosage (40mg/80mg) and combinatorial Azilsartan treatment with added drug. The following data was collected and analyzed for all study subjects enrolled in this observational study: Demographic details, Comorbidity associated with hypertension, Measurements of Systolic blood pressure (SBP), Diastolic blood pressure (DBP), Measurements of Systolic blood pressure (SBP3m) and Diastolic blood pressure (DBP3m) after 3 months of drug treatment. Results: The study population was predominantly of 51-60 years age group. Prevalence of hypertension at a gender level clearly showed that male population with 63% enrollment in study are at an increased risk in comparison to 37% patient enrollment noted in female population. Medical comorbidity ailments including Coronary Artery Disease, Diabetes Mellitus, Rheumatic Heart Disease. Azilsartan dosage (40mg/80mg) with either single treatment regime or combinatorial treatment regime with added drugs caused effective reduction in blood pressure during the study period. Conclusion: Combinatorial treatment regimens of Azilsartan (40mg/80mg) along with added drug, proved more effective in significantly lowering blood pressure levels. Keywords: Blood Pressure, Hypertension, Azilsartan, Comorbidity, Risk factors, Coronary artery disease(CAD), Diabetes mellitus, CAD/DM, Rheumatic heart disease (RHD). INTRODUCTION: High blood pressure or hypertension is well known as a ‘silent killer’, without exhibiting any major notable symptoms making it relatively undiagnosed. Hypertension is typically associated with a myriad of medical comorbidities such as cardiovascular ailments, neurological complications (stroke), nephrological ailments (chronic kidney diseases).etc making it a prominent medical comorbidity at a global level. [1,2] Further, hypertension